$RAPH
Raphael Pharmaceutical Inc.

2022 Q3 Form 10-Q Financial Statement

#000121390022047195 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.094M
YoY Change
% of Gross Profit
Research & Development $332.0K $84.00K $86.00K
YoY Change 106.21% -62.16%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $332.0K $84.00K $86.00K
YoY Change 106.21% -62.16%
Operating Profit -$1.426M -$612.0K -$175.0K
YoY Change 241.15% 58.96%
Interest Expense -$17.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$17.00K -$15.00K -$10.00K
YoY Change -950.0% 650.0%
Pretax Income -$1.443M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.443M -$627.0K -$185.0K
YoY Change 246.88% 62.02% -27.45%
Net Earnings / Revenue
Basic Earnings Per Share $0.10 $0.05 $0.01
Diluted Earnings Per Share $0.10 $0.05 $0.01
COMMON SHARES
Basic Shares Outstanding 15.23M shares 13.65M shares 13.04M shares
Diluted Shares Outstanding 15.06M shares 13.65M shares 13.04M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.00K
YoY Change
Cash & Equivalents $93.00K $135.0K $81.00K
Short-Term Investments
Other Short-Term Assets $26.00K $61.00K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $119.0K $196.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $119.0K $196.0K
Total Long-Term Assets $2.000K $0.00
Total Assets $121.0K $196.0K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $183.0K $78.00K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $183.0K $78.00K
Total Long-Term Liabilities $0.00
Total Liabilities $183.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$4.922M -$3.479M
YoY Change
Common Stock $155.0K $143.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$62.00K $118.0K $103.0K
YoY Change
Total Liabilities & Shareholders Equity $121.0K $196.0K
YoY Change

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.443M -$627.0K -$185.0K
YoY Change 246.88% 62.02% -27.45%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$374.1K -$82.00K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $2.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $580.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 416.3K $10.00K
YoY Change
NET CHANGE
Cash From Operating Activities -374.1K -$82.00K
Cash From Investing Activities 580.0
Cash From Financing Activities 416.3K $10.00K
Net Change In Cash 42.82K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$374.1K -$82.00K
Capital Expenditures $2.000K
Free Cash Flow -$376.1K -$82.00K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
272000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
14000 usd
dei Local Phone Number
LocalPhoneNumber
52-775-5072
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15225540 shares
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
269000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
196000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
422000 usd
CY2022Q2 us-gaap Assets
Assets
196000 usd
CY2021Q4 us-gaap Assets
Assets
422000 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
64000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53002
dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
dei City Area Code
CityAreaCode
(+972)
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
61000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
22000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
78000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
294000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14225540 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14225540 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12970540 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12970540 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
143000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
130000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3454000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2665000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3479000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2667000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
118000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
422000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
391000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
222000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
617000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
246000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
528000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
163000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-787000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-637000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-612000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-385000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2000 usd
us-gaap Net Income Loss
NetIncomeLoss
-812000 usd
us-gaap Net Income Loss
NetIncomeLoss
-642000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-627000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-387000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13342679 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10136451 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13647151 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10813649 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
128000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
161000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-185000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
103000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
352000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
290000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-627000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
118000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-255000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-298000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
370000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
506000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-387000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
191000 usd
us-gaap Net Income Loss
NetIncomeLoss
-812000 usd
us-gaap Net Income Loss
NetIncomeLoss
-642000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
290000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-258000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-199000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-66000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-330000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-434000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
174000 usd
cik0000141539 Issuance Of Common Stock And Warrant
IssuanceOfCommonStockAndWarrant
-312000 usd
cik0000141539 Issuance Of Common Stock And Warrant
IssuanceOfCommonStockAndWarrant
-370000 usd
cik0000141539 Cash Acquired In The Reverse Recapitalization
CashAcquiredInTheReverseRecapitalization
13000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
312000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
557000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
123000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218000 usd
cik0000141539 Current Assetsexcluding Cash And Cash Equivalents
CurrentAssetsexcludingCashAndCashEquivalents
-531000 usd
cik0000141539 Current Liabilities
CurrentLiabilities
38000 usd
cik0000141539 Reverse Recapitalization Effect On Equity
ReverseRecapitalizationEffectOnEquity
506000 usd
cik0000141539 Cash Acquired In Connection With Reverse Recapitalization Transaction
CashAcquiredInConnectionWithReverseRecapitalizationTransaction
13000 usd
CY2020Q4 cik0000141539 Issued And Outstanding Share Capital Description
IssuedAndOutstandingShareCapitalDescription
the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021.
CY2021Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
100 shares
CY2021Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
9459253 shares
CY2021Q2 cik0000141539 Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2021Q2 us-gaap Shares Issued
SharesIssued
1051028 shares
CY2021Q2 cik0000141539 Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2022Q2 cik0000141539 Accumulated Deficit
AccumulatedDeficit
3479000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70000 shares
CY2022Q2 cik0000141539 Purchase Warrants
PurchaseWarrants
100000 shares
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.5
CY2022Q2 us-gaap Investment Company Committed Capital
InvestmentCompanyCommittedCapital
550000 usd
CY2022Q2 cik0000141539 Company Raised Amount
CompanyRaisedAmount
250000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
250000 shares
CY2022Q2 cik0000141539 Purchase Warrants
PurchaseWarrants
100000 shares
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.13
CY2022Q2 cik0000141539 Companys Service Provider Consideration Of Past Services
CompanysServiceProviderConsiderationOfPastServices
250000 usd
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2022Q2 cik0000141539 Company Raised Amount
CompanyRaisedAmount
50000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001415397
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares

Files In Submission

Name View Source Status
0001213900-22-047195-index-headers.html Edgar Link pending
0001213900-22-047195-index.html Edgar Link pending
0001213900-22-047195.txt Edgar Link pending
0001213900-22-047195-xbrl.zip Edgar Link pending
cik0000141539-20220630.xsd Edgar Link pending
f10q0622ex31-1_raphael.htm Edgar Link pending
f10q0622ex31-2_raphael.htm Edgar Link pending
f10q0622ex32-1_raphael.htm Edgar Link pending
cik0000141539-20220630_lab.xml Edgar Link unprocessable
cik0000141539-20220630_def.xml Edgar Link unprocessable
cik0000141539-20220630_cal.xml Edgar Link unprocessable
cik0000141539-20220630_pre.xml Edgar Link unprocessable
f10q0622ex32-2_raphael.htm Edgar Link pending
f10q0622_raphaelpharm.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
f10q0622_raphaelpharm_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable